Cost-effectiveness of active monitoring versus antidepressants for major depression in primary health care: a 12-month non-randomized controlled trial (INFAP study).

Clinical practice guidelines for the treatment of major depressive disorder (MDD) recommend antidepressants for patients with moderate-severe depression and active monitoring for patients with mild-moderate symptoms. The feasibility and efficiency of active monitoring has not been proven conclusivel...

Descripción completa

Detalles Bibliográficos
Autores: Rubio-Valera M, Beneitez I, Peñarrubia-María MT, Luciano JV, Mendive JM, McCrone P, Knapp M, Sabés-Figuera R, Kocyan K, García-Campayo J, Serrano-Blanco A
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2015
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p7639
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=7639
https://pubmed.ncbi.nlm.nih.gov/25885818/
Access Level:acceso abierto
Palabra clave:Depressive Disorder
Antidepressive Agents
Active Monitoring
Watchful Waiting
Costs and Cost Analysis
Primary Health Care
Descripción
Sumario:Clinical practice guidelines for the treatment of major depressive disorder (MDD) recommend antidepressants for patients with moderate-severe depression and active monitoring for patients with mild-moderate symptoms. The feasibility and efficiency of active monitoring has not been proven conclusively. The aim of this study is to evaluate the cost-effectiveness of active monitoring in comparison to antidepressants for primary care patients with mild-moderate MDD.

Similares en LA Referencia